Short-term Outcomes for Patients and Providers After Elective Tracheostomy in COVID-19–Positive Patients by Murphy, Patrick et al.
Revised Oct 1, 2020 1
Short term outcomes for patients and providers following elective tracheostomy in 
COVID-19 positive patients 
Short Title: Tracheostomy in COVID-19 positive patients 
Patrick Murphy, MD, MPH, MSc, FRCSC 
Department of Surgery, Medical College of Wisconsin, WI, USA 
pbatesmurphy@gmail.com 
Emma Holler, BS 
Trauma and Acute Care Surgery, Eskenazi Health, Indianapolis, IN, USA 
emma.holler@eskenazihealth.edu 
Heidi Lindroth, PhD, RN 
Center for Health Innovation and Implementation Science, Center for Translational Science and 
Innovation, Indiana University School of Medicine, Indianapolis, IN, USA 
hlindrot@iu.edu 
Michelle Laughlin, MD   
Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA 
mrbraun@iupui.edu 
Clark J. Simons, MD  
Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA 
cjsimons@iupui.edu 
Erik W. Streib, MD  
Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA 
estreib@iupui.edu 
Malaz Boustani, MD, MPH 
Founding Director, Center for Health Innovation and Implementation, Indiana University School 
of Medicine, Indianapolis, IN, USA 
mboustan@iu.edu 
Damaris Ortiz, MD 
Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA 
damaorti@iu.edu 
Corresponding author: 
Damaris Ortiz, MD 
Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA 
damaorti@iu.edu 
_______________________________________________
This is the author's manuscript of the article published in final edited form as:
Murphy, P., Holler, E., Lindroth, H., Laughlin, M., Simons, C. J., Streib, E. W., ... & Ortiz, D. (2021). Short-term 
Outcomes for Patients and Providers After Elective Tracheostomy in COVID-19–positive Patients. journal of surgical 
research, 260, 38-45. https://doi.org/10.1016/j.jss.2020.10.013




Reprints: None requested 
Funding Sources: None 
Conference: None 
Conflict of Interest: None 
Keywords: COVID-19; coronavirus; tracheostomy; critical care 
 
Author Contributions: All authors contributed to the design of the study. EH, PM and DO 
collected data. EH, PM and DO performed analysis. PM and DO drafted the manuscript. All 
authors reviewed the data and provided critical revisions of the manuscript. 
Acknowledgements: Daniel Rydberg (Daniel.rydberg@eskenazihealth.edu), Respiratory 
Therapist, who was essential in developing the technique to minimize aerosolization during 
tracheostomy. Dr. Katie Stanton-Maxey (kajstant@iupui.edu) and Dr. Lindsey Mossler 
(liepeter@iupui.edu) were part of the surgical team and contributed to interdisciplinary 
discussions for tracheostomy indications and technique.  
  
  Revised Oct 1, 2020 3
Abstract 
 
Importance: Urgent guidance is needed on the safety for providers of percutaneous 
tracheostomy in patients diagnosed with COVID-19.  
Objective: Demonstrate that percutaneous dilational tracheostomy (PDT) with a period of 
apnea in patients requiring prolonged mechanical ventilation due to COVID-19 is safe and can 
be performed for the usual indications in the ICU. We hypothesize that the usual indications for 
tracheostomy including prolonged mechanical ventilation, high sedative requirements, and 
copious secretions apply to patients with COVID-19 and thus this diagnosis should modify 
tracheostomy technique but not change clinical indications. 
Design: Observational case series  
Setting: Single center medical intensive care unit at a Level-1 Trauma center 
Participants: Patients diagnosed with COVID-19 who were assessed for tracheostomy 
Main outcomes and measures: Success of a modified technique included direct visualization 
of tracheal access by bronchoscopy and a blind dilation and tracheostomy insertion during a 
period of patient apnea to reduce aerosolization. Secondary outcomes include transmission rate 
of COVID-19 to providers and patient complications. 
Results: From April 6th, 2020 to July 21st, 2020, 2,030 patients were admitted to the hospital 
with COVID-19, 615 required ICU care (30.3%), and 254 patients required mechanical 
ventilation (12.5%). The mortality rate for patients requiring mechanical ventilation was 29%. 18 
patients were assessed for PDT and 11 (61%) underwent the procedure. The majority had failed 
extubation at least once (72.7%) and the median duration of intubation prior to tracheostomy 
was 15 days (IQR 13-24). The median PEEP at time of tracheostomy was 10.8. The median 
PaO2/FiO2 ratio on the day of tracheostomy was 142.8 (IQR 104.5-224.4). Two patients had 
bleeding complications. At 1 week follow-up 8 patients still required ventilator support (73%). At 
the most recent follow-up 8 patients (73%) have been liberated from the ventilator, 1 patient 
(9%) died as a result of respiratory/multi-organ failure, and 2 were discharged on the ventilator 
(18%). Average follow-up was 20 days. None of the surgeons performing PDT have symptoms 
of or have tested positive for COVID-19. 
Conclusions and Relevance: Percutaneous dilational tracheostomy for COVID-19 patients is 
safe for healthcare workers and patients despite higher PEEP requirements, and should be 
performed for the same indications as other causes of respiratory failure. 
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Introduction 
The COVID-19 pandemic has presented many challenges to the medical community as 
we constantly adapt treatment guidelines based on what is learned daily about this novel virus. 
For surgeons, indications for tracheostomy for patients on prolonged mechanical ventilation due 
to COVID-19 has generated some controversy. Mechanical ventilation is required for the most 
severe cases of acute respiratory syndrome coronavirus-2 (COVID-19).1 Recent reports 
estimate 10%-15% of hospitalized patients required mechanical ventilation, and the median 
duration of mechanical ventilation was 7 days.1,2 However, for patients who have failed 
ventilator weaning and require prolonged intubation, tracheostomy must be considered. 
Prolonged endotracheal intubation has numerous detrimental effects including the potential for 
tracheal trauma, accidental extubation without a secure airway, difficulty weaning the ventilator, 
inability to communicate, continued delirium, and patient discomfort leading to high sedative and 
analgesic requirements.3 The goal of elective tracheostomy is to eliminate or reduce these risks 
to the patient while balancing the risk of an additional procedure.4 Generally accepted 
indications for elective tracheostomy include long-term mechanical ventilation, ventilator 
weaning failure, copious secretions, and airway obstruction and are typically performed at 1-2 
weeks. Major complications of tracheostomy are rare. Risk of mortality, tracheo-innominate 
fistula, and tracheo-esophageal fistula from this procedure are all less than 1%. Early bleeding 
complications at the stoma are more common with rates around 5%.3  
Elective tracheostomies in patients with COVID-19 present unique potential challenges: 
severe hypoxia due to high FiO2 and PEEP requirements,1,5,6 and risk of viral transmission to 
healthcare personnel. Early in the pandemic, several societies including the American Academy 
of Otolaryngology-Head and Neck Surgery published recommendations against performing 
elective tracheostomies in COVID-19.7,8 Concerns include unclear duration of viral shedding, 
risk of viral transmission to healthcare workers, and potential futility in the patients’ outcomes. 
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Other guidelines recommended waiting 2-3 weeks, requiring one or two negative COVID-19 
nasopharyngeal swabs and to consider performing the procedure open rather than 
percutaneous to decrease aerosolization.7,9 Guidelines thus far have not been based on clinical 
data, but rather on caution due to uncertain risk, and experience with similar epidemics, namely 
the Severe Acute Respiratory Syndrome (SARS) outbreak in the early 2000s.7,10 
 After the initial surge of patients with COVID-19 were admitted to the MICU in March 
2020, it became evident that recovery from this disease requires prolonged mechanical 
ventilation for some. After a multidisciplinary meeting between our division of acute care and 
trauma surgery, the medical ICU director, and respiratory therapy, we concluded that the usual 
indications for elective tracheostomy for prolonged mechanical ventilation would have the same 
benefits in patients with COVID-19,11 and developed a protocolized procedure for tracheostomy 
for COVID-19 positive patients.  
Now several months into the pandemic, more of the medical community, including the 
Society of Critical Care Medicine, has published that tracheostomies for patients with COVID-19 
are unavoidable in order to provide the standard of care.9 Every institution should develop 
practice guidelines to perform this procedure safely for their patients. In this paper we report on 





This is a retrospective observational study evaluating all tracheostomy consults for 
mechanically ventilated patients who were COVID-19 positive at a tertiary care, academic, 
Level-1 trauma center in Indianapolis, Indiana from April 6th, 2020 to July 21st, 2020. COVID-19 
infection was confirmed by nasal pharyngeal swab for reverse transcriptase polymerase chain 
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reaction (rtPCR) assay. Indiana University institutional review board approval (IRB # 
2004142964) was obtained prior to data collection. Informed consent was waived by the IRB. 
 
Patient Selection 
This study included all mechanically ventilated patients who were both COVID-19 
positive and received a consult for tracheostomy. Patients were cared for by the Medical 
Intensive Care Unit (MICU) and if the intensivist felt a tracheostomy was indicated he/she 
consulted the trauma surgeon on call. There were no predetermined criteria for tracheostomy. 
Each patient was evaluated individually by the trauma surgeon and appropriateness for 
tracheostomy was assessed by considering the patient prognosis and goals of care, potential 
benefit of the procedure, and stability to tolerate the procedure. A negative COVID test was not 
required. Patients with high ventilator settings (FiO2 ≥ 60%, PEEP ≥ 15 mmHg) and those in 
multi-organ failure with hemodynamic instability were deferred and re-assessed daily. For 
patients who had higher settings, a trial of apnea with paralysis for up to 3 minutes was 




 Percutaneous dilational tracheostomy (PDT) with a period of apnea was the preferred 
technique, performed at the patient’s bedside in a negative pressure ICU room, (Figure 1A). 
Personnel included two board-certified trauma surgeons who are surgical intensivists and also 
are the general surgeons for the hospital (one performed bronchoscopy and the other the PDT), 
a respiratory therapist (operating the ventilator) and two nurses (one administered medications 
and documented the procedure while the other was a runner that stood outside the room by a 
procedure cart). Extra sedation and paralytic medication was drawn up and ready in the room to 
avoid personnel entering and leaving during the procedure. All of the surgeons wore an N95 
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mask under a Powered Air-Purifying Respirator (PAPR). The other personnel remaining in the 
room for the duration of the procedure wore the following Personal Protective Equipment (PPE): 
N95 mask under a regular surgical mask OR a P100 reusable facemask with eye-protection, 
hair cover, isolation gown and single layer of gloves. 
 The patient was placed supine with a shoulder roll to extend the neck and was given 
sedation and paralytic medication. The cricoid cartilage was identified by palpation and a 
vertical incision was made. The subcutaneous tissue was bluntly dissected until the 2nd tracheal 
ring was identified. At this point a disposable bronchoscope was inserted into the endotracheal 
tube (ETT) through a bronchoscope adapter which was already attached to the ventilator tubing 
(Figure 1B). The ETT was retracted with the cuff down and the trachea was palpated to identify 
the entry point on bronchoscopy. A large bore needle was used to enter the trachea under direct 
visualization and a guidewire was threaded. The cuff was reinflated. At this time the inspiratory 
filter on the short corrugated tubing was disconnected from the ventilator and the patient was 
apneic (Figure 1C). The bronchoscope was removed and the rest of the procedure performed 
blind. The tract was dilated with a short dilator, then with the “Blue Rhino” dilator (COOK 
Medical). The tracheostomy was then inserted and the cuff inflated. The bronchoscope was 
inserted to confirm placement and the ETT was removed and placed into a medical waste bag. 
The inspiratory limb was then reattached.  
 
Outcomes 
The endpoints for this study were the short-term safety and feasibility for both patients 
and providers when performing PDT.  Baseline demographics, comorbidities, ventilator data, 
indications for tracheostomy, timing of the procedure, pre-procedural, intra-procedural and post-
procedural complications are reported. We also collected patient status at last follow-up and 
provider symptoms of or positive testing for COVID-19. Descriptive patient characteristics are 
described using medians (range) and frequencies.  
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Results 
 From April 6th, 2020 to July 21st, 2020, 2,030 patients were admitted with COVID-19, 615 
required ICU level care and 254 patients (12.5%) required intubation and mechanical ventilation 
for respiratory failure due to COVID-19. We were consulted on 18 patients and 11 underwent 
PDT (61%). Patient characteristics including demographics and Charlson Comorbidity Index are 
found in Table 1. The majority of these patients experienced shock (requiring vasopressor 
medications) prior to tracheostomy consult (11 of 18, 84.6%) and 13 required prone positioning 
(72.2%) for acute respiratory distress syndrome (ARDS). The majority of patients who 
underwent PDT failed extubation at least once (72.7%) and the median time to tracheostomy 
was 15 days (IQR 13-24) after initial intubation. The median time to tracheostomy after a 
COVID+ diagnosis was 19 days (IQR 15-24). Additionally, of the 11 patients who underwent 
PDT, 5 (45.5%) developed ventilator-associated pneumonia (VAP) prior to the procedure. The 
median PaO2/FiO2 ratio on the day of tracheostomy was 142.8 (IQR 104.5-224.4) and the 
average PEEP was 10.8 (SD 3.4). The median SOFA score during ICU stay was 8 (IQR 5-11). 
The median CAM-ICU and RASS scores on the day of tracheostomy were 7 (IQR 6-7) and -3 
(IQR -4, -2), respectively. Table 3 describes comorbidities and non-procedure related 
complications for all 18 patients who received a tracheostomy consult. Reasons for not 
performing tracheostomy were varied but the most common was that the patient was able to be 
extubated (57.1%). The described technique was successful in 100% of patients.  
 At 1-week follow-up, 8 (72.7%) of the tracheostomy patients remained ventilator-
dependent and none had died. Two patients had intra-procedural complications (18.2%) and 1 
patient had post-procedural complications (9.1%). During their hospital course, 8 (72.7%) of the 
patients who underwent tracheostomy were downsized and liberated from the ventilator, 1 died 
(9.1%), and 2 (18.2%) were discharged on the vent. Hospital course after tracheostomy can be 
found in Table 2. None of the surgeons have demonstrated symptoms of COVID-19. 




We have demonstrated the feasibility and safety of a modified technique for bedside 
percutaneous tracheostomy including a period of apnea and the use of PAPRs for PPE. PDT 
was performed for usual indications for respiratory failure. All tracheostomies were performed in 
patients requiring prolonged mechanical ventilation due to COVID-19. This was accomplished 
with a multi-disciplinary team of surgeons, intensivists, nurses and respiratory therapists.  
 
Development of Tracheostomy Technique 
Our technique was refined and informed by key observations during the initial 
tracheostomies. Isolation precautions highlighted the importance of preparation, particularly in 
case of unforeseen equipment failure or complications (e.g. bending of wire, contamination of 
instruments, unexpected bleeding). We adapted and created a role of a designated “runner” to 
address this need. The “runner” was a nurse who stood outside the room and was ready to 
address unanticipated needs with a procedure cart with additional supplies, including an extra 
tracheostomy kit. In addition, communication emerged as a critical component. The PAPR 
motor is quite loud and limited intraprocedural communication. To address this, we performed a 
huddle with the procedure team prior to starting the tracheostomy to clarify each person’s role, 
position, and appropriate time to disconnect the ventilator. This huddle minimized confusion and 
procedure time. Finally, several techniques were initially employed in order to minimize 
aerosolization. During the first tracheostomy, the long limb tubing to the endotracheal tube was 
disconnected and the end of the tubing was then covered by the respiratory therapists’ hand 
while the airway was serially dilated and the tracheostomy was placed. Another technique 
initially employed was turning off the ventilator completely and bagging the patient up until the 
airway was accessed and dilated. The ventilator was then turned on and connected to the 
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tracheostomy after placement. After discussions between the surgeons and respiratory 
therapists after these initial tracheostomies, the preferred technique to minimize aerosolization 
through apnea during the procedure was to disconnect the inspiratory limb of the ventilator after 
gaining wire access to the trachea, and to minimize the amount of time the bronchoscope is in 
place after confirming appropriate tracheal access. This technique is simple, does not require 
shutting off the ventilator and restarting it, and only clean air from the vent itself is expelled into 
the room. Other principles of the protocol to improve staff safety included minimizing personnel 
in the room, use of appropriate PPE, and keeping the room door closed during and then after 
the procedure for 45 minutes. No trainees were involved in these procedures. 
 
Indications and Timing of Percutaneous Tracheostomy 
 Given the limited data available about COVID-19 infection, our institution relied on data 
describing traditional benefits of percutaneous tracheostomy for prolonged ventilation for acute 
respiratory distress syndrome from other causes.10,11 These potential benefits include ability to 
wean sedation and increase patient communication, management of secretions, and to facilitate 
long-term vent weaning with decreased ventilator days.12 Given that the duration of viral 
shedding and infectivity of COVID-19 is unknown and that early tracheostomy has no 
established mortality benefit,11 patients were generally not considered for tracheostomy until 
they were mechanically ventilated for 10-14 days. Recent evidence suggests that maximum 
viral shedding occurs within the 5 days after symptom onset.13 When considering tracheostomy, 
the ability to wean sedation was of particular importance due to medication shortages. PPE 
shortages were not a consideration, as protocols were instituted early to conserve and re-use 
PPE in the hospital. When determining the next steps for patients requiring prolonged 
ventilation, goals of care discussions were vital. This was especially pertinent for patients 65 
years of age or older, as studies have shown that tracheostomy for non-surgical causes is 
associated with a higher 1-year mortality.14 The healthcare team along with the palliative care 
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team held discussions with family and the patient if possible, surrounding tracheostomy and the 
implications of prolonged mechanical ventilation. This ensured that plans of care were 
consistent with the patient’s wishes. 
 Reluctance to perform tracheostomy for prolonged mechanical ventilation in COVID-19 
positive patients has in part been driven by perceived lack of beneficence, as mortality rates for 
critically ill and ventilated patients were reportedly high. A single-center experience in Wuhan 
China reported a 61.5% mortality rate in 28 days of follow-up.4 A report from the Lombardy, Italy 
region reported a 26% mortality rate for critically ill patients in the ICU.3 The largest study from 
New York initially reported mortality rates of 76.4% and 97.2% for those who received 
mechanical ventilation in the 18-65 year old age group and those older than 65 years old, 
respectively. These results have since been corrected to an overall mortality rate of 24.5% for 
patients who required mechanical ventilation.1 At our institution the mortality rate for patients 
with COVID-19 requiring mechanical ventilation is 29%. This is better than recently reported 
mortality rates for ARDS of all etiologies since 2010: 45% in-hospital, 38% ICU, 30% 28/30-day, 
and 32% 60-day mortality.15 Tracheostomies are inevitably required in order to provide 
comprehensive care to those on prolonged mechanical ventilation. We have shown that with 
proper PPE, precautions, and a structured team approach16, healthcare providers can safely 
perform percutaneous tracheostomy for COVID-19 positive patients.  
 
Preference for Percutaneous Technique 
Aerosolization risk during tracheostomy has led other groups to consider novel 
techniques of tracheostomy,17 or to preferentially perform an open tracheostomy.18 We were 
successful in performing bedside percutaneous tracheostomy in all our patients with few 
modifications to the traditional technique. The benefits of using the percutaneous technique 
include using the patient’s ICU room for the procedure, thus not requiring operating room 
personnel to be in contact with the patient, conserving operating room resources, and limiting 
  Revised Oct 1, 2020 12
patient travel which can theoretically lead to increased viral exposure and also compromise the 
patients’ tenuous respiratory status. In addition, the percutaneous technique is the preferred 
technique by the surgeons at this institution, leading to comfort and skill with the procedure. 
Procedure set-up time including patient positioning, the team huddle, time-out, and donning of 
PPE took about 30 minutes. Total time of the procedure excluding set-up time was 3-5 minutes, 
and time in the actual airway was 1-2 minutes.  
 
Observations 
 While the sample size is small, some observations are notable. Ventilator-associated 
pneumonia was common, noted in 9 (50.0%) of the patients consulted for tracheostomy and in 7 
(63.6%) of patients who underwent the procedure. In addition, all of the patients who required 
percutaneous tracheostomy were Hispanic/Latino or African-American. The median age was 54 
(25-74) years old and most patients were male, 90%. Finally, the median CAM-ICU-7 and RASS 
scores on the day of percutaneous tracheostomy were 7 (IQR 6-7) and -3 (IQR -4, -2), 
respectively. These scores indicate severe delirium and a moderate level of sedation, both of 
which are linked to worsening outcomes.19 At 1-week follow-up, 6 of the 11 tracheostomy 
patients continued to have positive CAM-ICU-7 scores. As previous studies have shown, 
COVID-19 patients have an estimated delirium prevalence rate of 73.6%.20 Future studies 
should investigate underlying factors for the disproportionately higher number of cases and 
more severe cases of COVID-19 observed in ethnic minority groups.  
 
Strengths and Limitations  
 Our study is not without limitations. There is a clear selection bias for who received a 
tracheostomy favoring patients who are expected to recover. Notably, only 11 of 18 patients we 
were consulted on received a tracheostomy. Further, our sample was small and limited to a 
single center, reducing generalizability and external validity. Also, due to ethical limitations we 
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do not have confirmation on the absence of symptoms for respiratory therapy and nursing staff. 
Our hospital has performed random mitigation testing and no tracheostomy providers have 
tested positive. Finally, we do not have a comparison group to establish the potential benefits of 
tracheostomy, although this has been established in similar disease processes.10  
 Of note, a series of 96 patients who underwent a novel percutaneous tracheostomy 
utilizing the bronchoscope outside of the ETT has established safety and efficacy of their 
technique in short-term follow-up (average 18 days) and has comparable patient outcomes to 
our institution.17  In addition, a recent publication has described a protocol for percutaneous 
tracheostomy with a period of apnea to minimize aerosolization. This series focuses on the 
description of the technique.21 We describe a different technique utilizing apnea to minimize 
aerosolization, which was performed only on patients with COVID-19 infection, and with a PEEP 
cut-off of 15, which is higher than previously described thresholds. Our description of outcomes 
is the first to include delirium and delirium severity in patients with respiratory failure due to 
COVID-19 who require tracheostomy. In addition, to our knowledge, we are the first to describe 
the routine use of PAPRs for PPE during tracheostomy. In later follow-up studies, comparison of 
effectiveness of PPE types will be important in limiting infection transmission and conserving 
resources. This paper is an important addition to early literature regarding care for the COVID-
19 positive patient. We provide a thorough description of considerations for and a safe modified 
technique of percutaneous tracheostomy despite a higher PEEP threshold. 
 
Conclusions 
 Percutaneous tracheostomy can be safely performed in patients diagnosed with COVID-
19 for the usual indications, with a modified technique to minimize aerosolization. As we 
continue to care for more patients with COVID-19, development of institutional protocols for safe 
performance of tracheostomy will be required for prolonged ventilator weaning. Comparison of 
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outcomes from described protocols can help establish evidence-based standards of care for 
patients with respiratory failure from COVID-19.  
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Figure 1: (A) Personnel and positioning for percutaneous tracheostomy. (B) Bronchoscopy 
performed to directly visualize needle access to trachea. (C) Inspiratory filter disconnected for 
apnea period to limit aerosolization.  
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Table 1 – Patient characteristics of patients diagnosed with COVID-19 considered for PDT  





Trach indication  PDT Treatment Died 




Y HQ + AZ, IV steroids, Lasix N 





Y HQ + AZ, IV steroids, Lasix N 




HQ + AZ, Tocilizumab, IV 
steroids, Lasix, CVVH, 
convalescent plasma 
Y 
4 43 F White Hispanic/Latino 1 27 Prolonged ventilation Y HQ + AZ, IV steroids N 





HQ + AZ, tocilizumab, IV 
steroids, Lasix 
N 
6 55 M Black 
Not 
Hispanic/Latino 
1 24 Prolonged ventilation Y HQ + AZ, IV steroids, Lasix N 





HQ + AZ, tocilizumab, IV 
steroids, Lasix, CVVH 
N 





HQ + AZ, IV IV steroids, 
Lasix 
N 
9 53 M White Hispanic/Latino 1 21 Prolonged ventilation Y HQ + AZ, Lasix N 








HQ + AZ, tocilizumab, full 
anticoagulation, Lasix 
N 
11 60 F Black 
Not 
Hispanic/Latino 
0 27 Prolonged ventilation Y 




12 52 M White 
Not 
Hispanic/Latino 
0 30 Prolonged ventilation N HQ + AZ, Lasix N 
13 65 F Black 
Not 
Hispanic/Latino 
6 36 Prolonged ventilation N HQ + AZ, IV steroids, Lasix Y 
14 66 F White 
Not 
Hispanic/Latino 
4 63 Prolonged ventilation N 




15 72 M Asian 
Not 
Hispanic/Latino 
1 28 Prolonged ventilation N HQ + AZ, tocilizumab, Lasix N 
16 48 M White Hispanic/Latino 1 24 Prolonged ventilation N 
HQ + AZ, IV steroids, full 
anticoagulation, Lasix 
Y 
17 59 F White Hispanic/Latino 1 28 Prolonged ventilation N 
HQ + AZ, IV steroids, full 
anticoagulation, Lasix 
N 
18 51 M White Hispanic/Latino 1 25 Prolonged ventilation N 
Remdesivir, IV steroids, full 
anticoagulation, Lasix 
N 




Table 2 – Outcomes of patients diagnosed with COVID-19 undergoing elective PDT  










Status at 1-week 
post-PDT 
Hospital course after trach Length of 
follow-up, 
days 
1 13 3 Bleeding None On vent, AC/VC Developed VAP. Trach downsized on 
HD 30. Discharged home on RA on HD 
31 
18 
2 23 1 None None On vent, AC/VC Discharged home on 3L oxygen on HD 
74 
52 
3 14 0 None None On vent, AC/VC Died from COVID complications on HD 
26 
12 
4 13 1 None None On vent, PSV Trach downsized on HD 26. 
Discharged home on RA on HD 30 
14 
5 14 1 None None No ventilator Trach downsized on HD 25. 
Discharged home on RA on HD 33 
19 
6 24 0 None None On vent, AC/VC Trach downsized on HD 35. 
Discharged to inpatient rehabilitation 
with trach collar 30% O2 on HD 48 
26 
7 21 2 None None No ventilator Discharged on RA to acute rehab on 
HD 37. 
15 
8 15 1 None Bleeding 
during trach 
change 
On vent, AC/VC Trach downsized on HD 27. 
Decannulated on HD 39, discharged to 
SNF on HD 51 
36 
9 24 1 None None No ventilator Trach downsized on HD 30. 
Discharged on RA to LTACH on HD 35 
11 
10 28 1 None None On vent, AC/VC Developed VAP, sepsis. Discharged on 
ventilator to LTACH on HD 44 
14 
11 8 0 Pneumothorax None On vent, AC/VC Discharged on ventilator to LTACH on 
HD 33 
12 











Asthma, n (%) 2 (11.1) 1 (9.1) 1 (14.3) 
Diabetes, n (%) 10 (55.6) 5 (45.5) 5 (71.4) 
Hypertension, n (%) 11 (61.1) 7 (63.6) 4 (57.1) 
Liver disease or cirrhosis, n (%) 2 (11.1) 1 (9.1) 1 (14.3) 
Obesity (BMI ≥30 kg/m
2
) , n (%) 5 (27.8) 2 (18.2) 3 (42.9) 
Evidence of bacterial or viral co-
infection at admission, n (%) 
4 (22.2) 2 (18.2) 2 (28.6) 
Pulmonary embolism, n (%) 1 (5.6) 0 (0.0) 1 (14.3) 
DVT, n (%) 4 (22.2) 4 (36.4) 0 (0.0) 
Sepsis, n (%) 7 (38.9) 4 (36.4) 3 (42.9) 
Septic shock, n (%) 14 (77.8) 7 (63.6) 7 (100.0) 
VAP, n (%) 9 (50.0) 7 (63.6) 2 (28.6) 
BMI=Body Mass Index; DVT=Deep Vein Thrombosis; VAP=Ventilator associated pneumonia 
 

